The US FDA's new guideline suggests using "Generally Accepted Science Knowledge" (GASK) to develop nonclinical testing protocols for developing drugs and biologicals to remove unnecessary testing. Interpreting acceptable scientific knowledge as a rational approach has motivated the author to suggest substantial changes to the development of biosimilars, as demonstrated in this paper. The FDA can accept these suggestions without requiring any legislative change to the Act that defines such requirements. Suggested here is the waiving of clinical efficacy testing due to its lower sensitivity compared to analytical and functional testing and pharmacokinetic profiling. Also questioned is the need to test pharmacodynamic markers that do not correlate with clinical response and find new biomarkers requiring extensive testing to validate their use. Should the FDA accept these scientifically rational suggestions, it will significantly reduce the time and cost of approving biosimilars without safety or efficacy risk, as justified based on acceptable scientific knowledge and rationality.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674418 | PMC |
| http://dx.doi.org/10.3390/ph16111517 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The United States Food and Drug Administration's Platform Technology Designation to Expedite the Development of Drugs.
Pharmaceutics
July 2024
College of Pharmacy, University of Illinois, Chicago, IL 60612, USA.
Drug development costs can be significantly reduced if proven "platform" technologies are allowed to be used without having to validate their use. The most recent US Food and Drug Administration (FDA) guideline brings more clarity, as well as a greater focus on the most complex technologies that can now be used for faster drug development. The FDA has highlights the use of lipid nanoparticles (LNPs) to package and deliver mRNA vaccines, gene therapy, and short (2-20 length) synthetic nucleotides (siRNA).
View Article and Find Full Text PDFPyrimethamine reduced tumour growth in pre-clinical cancer models: a systematic review to identify potential pre-clinical studies for subsequent human clinical trials.
Biol Methods Protoc
March 2024
Department of Biomedical Sciences, Asia Metropolitan University, Johor Bahru 81750, Johor, Malaysia.
Pyrimethamine (PYR), a STAT3 inhibitor, has been shown to reduce tumour burden in mouse cancer models. It is unclear how much of a reduction occurred or whether the PYR dosages and route of administration used in mice were consistent with the FDA's recommendations for drug repurposing. Search engines such as ScienceDirect, PubMed/MEDLINE, and other databases, including Google Scholar, were thoroughly searched, as was the reference list.
View Article and Find Full Text PDFCharacterization of accelerated approval status, trial endpoints and results, and recommendations in guidelines for oncology drug treatments from the National Comprehensive Cancer Network: cross sectional study.
BMJ Med
April 2024
Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Article Synopsis
- The study assessed how the National Comprehensive Cancer Network (NCCN) guidelines reflect updates on oncology drugs that received accelerated approval from the FDA between 2009 and 2018.
- It found that while all indications were included in NCCN guidelines, only a small percentage of them accurately reported the accelerated approval status, with most postapproval trials confirming drug benefits.
- Additionally, NCCN guidelines often updated their recommendations based on FDA decisions about drug approval statuses, aligning closely with both positive and negative outcomes from confirmatory trials.
A network of regulatory innovations to improve FDA quality assessments of human drug applications.
Int J Pharm X
June 2024
Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, MD 20993, United States of America.
A network of regulatory innovations brings a holistic approach to improving the submission, assessment, and lifecycle management of pharmaceutical quality information in the U.S. This dedicated effort in the FDA's Center for Drug Evaluation and Research (CDER) aims to enhance the quality assessment of submissions for new drugs, generic drugs, and biological products including biosimilars.
View Article and Find Full Text PDFNarrative Review: The FDA's Perfunctory Approach of Dietary Supplement Regulations Giving Rise to Copious Reports of Adverse Events.
Innov Pharm
October 2023
College of Pharmacy, Nova Southeastern University.
Article Synopsis
- The FDA was established by the 1906 Pure Food and Drugs Act to combat misbranding and adulteration in consumer products, promoting public health through regulation of foods, drugs, and cosmetics.
- The 1994 Dietary Supplement Health and Education Act (DSHEA) provided a framework for dietary supplements, establishing labeling requirements but leaving the FDA's regulation of this market lacking.
- The study investigates how weak FDA regulations on over-the-counter dietary supplements have led to adverse health effects in consumers, with notable harmful products identified through case studies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!